VERU Veru Inc.
$2.44▼ -2.40%
Healthcare
Other
After hours
$2.44▲ +0.00%
Sep 11, 7:30 PM ET
Volume 235.4K
Avg Volume (10D) 287.7K
Key Metrics & Fundamentals
Market Cap
$41.60M
P/E Ratio
–
Div Yield
–%
52W Range
2.05 - 7.33
% vs 50 MA
-4.01%
% vs 200 MA
-2.14%
RSI-14
42.0
MACD Histogram
-0.0300
Beta (1Y vs SPY)
2.27
Free Cash Flow
-$5.47M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$8.23M
COGS
–
Operating Exp
$7.71M
Operating Income
-$7.71M
EBIT
-$7.71M
Pretax Income
-$6.99M
Net Income
-$6.99M
EPS (Diluted)
-0.30
Price & Volume History
Loading chart…
Recent News
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
GlobeNewswire · Sep 8, 2026 12:17 PM
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
GlobeNewswire · Sep 2, 2026 12:30 PM
Veru (VERU) Q3 2026 Earnings Call Transcript
Motley Fool · Aug 17, 2026 11:58 AM
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
GlobeNewswire · Aug 10, 2026 10:30 AM
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
GlobeNewswire · Aug 4, 2026 12:30 PM
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
GlobeNewswire · Aug 3, 2026 12:30 PM
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
GlobeNewswire · Jul 30, 2026 12:30 PM
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires · Jul 27, 2026 7:56 PM
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
GlobeNewswire · Jul 27, 2026 12:10 PM
Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty
PR Newswire · Jul 9, 2026 9:30 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See VERU's money flow as a full page
Social Sentiment
Avg -0.50 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.